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all leaves was considered satisfactory. This condition was 
fulfilled by 36 of 44 participants. Follow-up of unsatisfactory 
results is on-going. 
 
Conclusions: The pilot audit of MLC performance has proven 
that the methodology for this audit worked well. About 80% 
of participants achieved satisfactory results. The hospitals 
with poor results were alerted of their MLCs sub-optimal 
performance. The positional accuracy of MLCs recorded in 
this audit is indicative of the accuracy relevant to clinical 
IMRT procedures. 
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Purpose/Objective: With regard to the complex dose 
distributions produced by active raster scanning, each 
treatment plan has to be verified before treatment. At the 
Heidelberg Ion-beam Therapy Center (HIT) patient specific 
dose verification is currently performed by using an array of 
24 ionization chambers. Due to the limited sampling period 
(~14 mm) of this system, a high resolution (~0.2 mm) flat 
panel detector has been investigated to supplement these 
dose measurements with fluence measurements in the dose 
plateau area of the depth dose distributions. 
Materials and Methods: A procedure is presented to correct 
the flat panel raw data and convert the corrected data into 
fluence distributions after suitable energy calibration. In the 
present work the fluence measurements have been realized 
using patient relevant accelerator settings. Additionally, a 
state of the art flat panel detector (XRD 0822 without 
scintillator, Perkin Elmer, Germany) was investigated with 
respect to signal quality and mandatory image corrections. 
After each measurement, the generated fluence distributions 
are checked against expected fluence distributions calculated 
from respective beam parameters. Using this method, 
fluence distributions can additionally be checked for each iso 
energy layer. To quantify the agreement between the 
measured and calculated fluence distributions a gamma index 
analysis has been performed. A global gamma index criterion 
of 5 % fluence deviation and 1 mm distance to agreement was 
used. Values below 3 % of the fluence maximum in each iso 
energy layer have not been taken into account.  
Results: Treatment plans with up to 2-3 Gy can be measured 
at the highest available beam intensity without any effects of 
detector signal saturation. So far, 6 proton treatment plans 
and 12 carbon ion treatment plans have been investigated. 
Averaged over all treatment plans, the gamma-index 
criterion was met in more than 98 % of the fluence values for 
protons and more than 96 % for carbon ions.  
Conclusions: A specific protocol was established to process 
flat panel raw data: It contains necessary offset, gain and 
bad pixel corrections, as well as an energy calibration. Based 
on two-dimensional high resolution fluence measurements in 
the dose plateau area of the depth dose distributions it is 
possible to provide supplementary information to 
conventional dose measurements. The corrected and 
calibrated flat panel detector signal shows promising results 
compared to the calculated data. However, before using this 
protocol in clinical routine, further studies, especially 
towards irradiation damage of the detector, have to be 
performed. So far, further bad pixels have not been 
detected.  
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Purpose/Objective: Flattening Filter Free (FFF) radiotherapy 
has recently become widely discussed in particular for 
stereotactic treatments where large doses per fraction (frac.) 
can be delivered quicker due to the higher dose rate. 
However, the original idea of FFF was not mainly to increased 
dose rate, but instead to reduce head scatter and thereby 
scattered dose to the entire patient. The purpose of this 
study was to investigate if normal fractionated treatments 
(1.8 – 2.0 Gy per frac.) could be delivered with clinically 
relevant dose accuracy and if there were any gains in 
treatment delivery because of the higher dose rate, or gains 
in treatment plans from the reduced scatter.  
Materials and Methods: In three of the main radiotherapy 
treatment sites (brain, head and neck (H&N) and lung) the 
first 10 curatively treated patients in 2014, having a single 
target and treated with a single full or half VMAT arc were 
selected. The patients were re-planned on Pinnacle ver. 9.8 
for the Elekta Versa HD linac. The dose prescriptions were 
59.4 Gy in 33 frac. for brain and 66 Gy in 33 frac. for H&N 
and lung. For each patient two plans were created with 
different beams (6 MV and 6 MV FFF). Both plans were 
optimised with the same fixed number of iterations and with 
no change to VMAT objectives. All treatment plans were 
delivered and dose accuracy evaluated using the Sun Nuclear 
ArcCheck phantom and analysed using a 3% and 3 mm global 
gamma between planned and measured doses. Beam on times 
were recorded for treatment beams. All DVH metrics were 
tested for significant differences with a paired two-sided 
Wilcoxon-signed rank test, with a significance level of 5%. 
Results: The mean dose to the body is reduced in the FFF 
treatment plans compared to the FF (Flattening Filter) plans 
for all 3 treatments sites (p=0.05, see table). For brain and 
H&N there are only small differences in target dose, however 
for the lung treatment PTV D2% (near max) and D98% (near 
minimum) the FFF plans are slightly less favourable. For H&N 
the FFF delivery is slower to deliver despite the higher dose 
rate. This might be due to the higher MLC modulation needed 
to compensate for the inhomogeneous profile of the FFF 
beam. The higher MLC modulation effect is seen for all three 
sites in the number of MU needed for the plans (p=0.002). 
The pass rate from the ArcCheck measurements are all 
